Read More Analyst Ratings Peeling Back The Layers: Exploring Vontier Through Analyst Insights By Benzinga Insights February 16, 3:01 PM During the last three months, 4 analysts shared their evaluations of Vontier (NYSE:VNT), revealing diverse outlooks from bullish… VNT
Read More Biotech General News Achieve Life Sciences Announces Publication Of Cytisinicline Vaping Cessation Trial Results In JAMA Internal Medicine; Phase 2 ORCA-V1 Trial Showed Treatment With Cytisinicline More Than Doubled Odds Of Quitting E-Cigarettes Compared With Placebo By Benzinga Newsdesk May 6, 11:18 AM Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo Cytisinicline treatment well tolerated with no serious adverse events ACHV
Read More Analyst Ratings News Price Target Raymond James Maintains Strong Buy on National Retail Props, Lowers Price Target to $48 By Benzinga Newsdesk October 4, 8:17 AM Raymond James analyst RJ Milligan maintains National Retail Props (NYSE:NNN) with a Strong Buy and lowers the price target from $52 to $48. NNN
Read More Short Ideas Short Sellers Trading Ideas (LMND) – Analyzing Lemonade’s Short Interest By Benzinga Insights April 25, 1:45 PM Lemonade’s (NYSE:LMND) short percent of float has risen 4.5% since its last report. The company recently reported that… LMND